Chemoprophylaxis may be a prevention strategy for the sexual transmission of human immunodeficiency virus (HIV). Evidence suggests that condom use has waned with the availability of antiretroviral medication, at least in some resource-rich settings. Barrier methods of HIV prevention have inherent problems, and the potential for failure. Microbicide research has focused primarily on male-to-female transmission. Analogous to post-exposure prophylaxis, HIV prevention may be achieved by preexposure prophylaxis in some settings. Research in this potential strategy may be rewarding.
Individuals continue to be infected with HIV sexually, and by mother-to-child transmission in all communities at differing rates, depending on socio-political determinants such as gender, education, income, and sexuality. There is little evidence of a significant reduction in global rate of infection over time. HIV still spreads like wild-fire in vulnerable communities, 5 and is increasingly of multi-drug-resistant virus strains. 6 These communities subsequently respond in a way that may limit further dissemination, usually after a combination of epidemic saturation and adoption of avoidance prevention strategies. In Thailand, for example, the aggressive promotion of partner reduction and condom use appears to have significantly slowed transmission. 7 Circumcision has been noted to be partly protective against HIV transmission but has only been studied in a heterosexual African setting. 8 While treatment for HIV-infected individuals now includes an impressive and increasing armamentarium of antiretroviral agents, the quest for an effective preventative vaccine for the uninfected has been, to date, less fruitful. 9 Many putative vaccines are in development, but the correlates of protective immunity against HIV-if indeed it is possible in humansremain unclear. Only one vaccine has been studied in a large-scale controlled study. Even though funds have been established for both research and eventual purchase of vaccines, the availability of new candidate vaccines is limited. Since safety issues remain paramount, few large prevention studies are likely to be planned in the near future. Two novel approaches to establish a long-lasting broad immune response against HIV are priming with naked DNA, and boosting with sub-unit vaccines. However, concerns exist that the breadth and durability of anti-HIV immune responses may be too narrow to elicit complete protection against the myriad of HIV viral strains currently circulating in humans. Viral escape from cytotoxic T-lymphocyte recognition might be a limiting factor to vaccine efficacy. 10 In addition, recent documented evidence of superinfection illustrates the problems facing the search for a prophylactic vaccine. 11 Significant numbers of individuals are at high risk of imminent HIV infection, such as those in HIV serodiscordant sexual partnerships, or in those who choose not to use condoms. For these individuals, a current vaccine strategy remains far in the future.
Although the rate of condom failure when used correctly is probably very low, only a single failure may result in an additional HIV-infected individual.
One response to other infectious agents in the absence of an effective preventative vaccine combines behaviour for avoidance of the pathogen, with or without chemoprophylaxis. For centuries, malaria has ravaged many parts of Africa, South America, and Asia, and at some times in the past, Europe. The discovery of quinine was the first of a cascade of therapeutic and prophylactic agents that allowed non-immune individuals to visit or live in endemic areas with greater safety. 12 These drugs have usually been used in association with avoidance strategies such as mosquito nets, topical agents, and bio-control methods. This approach is not devoid of problems, including user variability, toxicity, the evolution of resistance to the prophylactic agents, and the loss of herd immunity. Malaria prophylaxis is mainly used by visitors to an endemic area and incurs significant financial and practical cost. However, this preventative strategy is successful in limiting the effects of an infectious agent such as malaria in a non-immune population.
In the same way as infection with malaria is usually infrequent, one could argue that the percentage of time that an individual is at risk of HIV infection is relatively low, since it represents an intermittent rather than a continuous exposure to the pathogen. Exposure through having sex with an HIV-infected individual within the human population occurs at a variable rate, as does exposure to malaria from an infected mosquito. Extending the prophylaxis analogy to HIV, the use of barriers to prevent infection is the current favoured methodological approach, and appears to be highly effective. Condoms have dramatically reduced sexual infection rates in higher risk populations. They are extremely successful at preventing sexual transmission of HIV, but breakage does occasionally occur. Breakage may result in an exposure risk, which could potentially be reduced by using chemoprophylactic intervention. Perhaps more frequent is non-use of condoms, which represents a much greater risk. The risk may be significantly reduced by HIV chemoprophylaxis. Individuals who do not use condoms, for whatever reason, may find taking a prophylactic agent more acceptable. There are often expressed fears that any such chemical intervention could reduce reliance on condoms or other mechanical barriers to protection. This risk compensation phenomenon was previously seen with the introduction of seat belt use in cars. Intervention resulted in enhanced safety of the driver, but this was offset by increased pedestrian road deaths, perhaps due to more reckless driving. 13 Any intervention to reduce risk of HIV infection may provide an opposite and negative effect on risk. An increase in risk-taking may result from a perceived reduction in that risk.
Currently, the use of chemoprophylaxis to prevent HIV infection has been limited to the obstetric arena. Several strategies have been undertaken, including treatment of the mother pre-and peripartum, and the use of zidovudine (ZDV) in the neonate. 14 Uncertainty remains as to which intervention phase has the dominant protective effect, although longer and better treatment of the mother appears to confer greater protection to the child. There have also been calls for the development and testing of topical virucides for vaginal and rectal use. 15 Occupational and sexual post-exposure prophylaxis (PEP) is advocated for individuals who have been exposed to HIV, although no controlled studies exist to justify this intervention. A non-randomized, case control study of 33 cases and 665 controls in a multivariate model suggested that the use of ZDV could reduce HIV transmission, when given after exposure to HIV. 16 Zidovudine-treated patients were 81 percent less likely to have contracted HIV infection. Deep needlestick injury, visible blood, and more severe illness in the source patient were all independent risk factors for seroconversion.
No discussion to date has occurred regarding the possibility of pre-exposure prophylaxis (PREP) in combination with condom use as an HIV prevention strategy. The first agents available to treat HIV infection were the nucleoside reverse transcriptase inhibitors (NRTIs)-such as ZDV, lamivudine (3TC), and didanosine (ddI) -which require intracellular phosphorylation before they can act as DNA chain terminators. The nucleotide RT inhibitors (NtRTIs)-such as tenofovir (TDF)-also require intracellular phosphorylation to have activity. In contrast, the non-nucleoside reverse transcriptase inhibitors (NNRTIs)-such as nevirapine (NVP) and efavirenz (EFV) -do not have activity, allowing for more rapid antiviral action. The development of HIV fusion inhibitors, such as enfuvirtide (T-20), and co-receptor blockers, such as SCH-D, has offered the possibility of pre-integration blockade of HIV, and therefore of host cell protection.
There are several requirements for an ideal agent that could act in a similar way to a malarial prophylactic agent. The agent should prevent infection of cells, or at least nuclear integration, when exposed to HIV. It should be a once-daily or less frequently taken agent that is non-toxic, well tolerated, and easily administered. Such an ideal agent does not yet exist for the prevention of malaria, but chemoprophylaxis is still accepted as appropriate for visitors to endemic areas with high risk of exposure to this pathogen. The analogy could extend to HIV-negative individuals who enter an "endemic area" (eg, by having sex), but are only sporadically exposed to virus. Adequate prophylaxis may be possible with intermittent pre-sexual exposure use of anti-HIV agents, although the time to reach therapeutic levels of drug may also be important.
Many problems such as uptake, cost, and development of resistance exist with this intervention, so that malarial prophylaxis may be a good model for preexposure prophylaxis against HIV. The risk:benefit ratio must be of paramount importance in the consideration of this approach for HIV prevention. HIV serodiscordant couples, commercial sex workers, women wishing to conceive, and individuals unwilling to use condoms are groups that are regularly at significantly higher risk of HIV infection than the general population. Could these groups now benefit from HIV pre-exposure chemoprophylaxis with current or soon-to-be available drugs?
The availability of once-daily therapy such as TDF with low reported rates of toxicity (although yet to be empirically demonstrated in long-term treatment), has impressive post-exposure activity against HIV in simian studies. [17] [18] [19] This could perhaps change the way we approach prevention of HIV infection. Studies of post-exposure treatment in animals have suggested that HIV infection can be prevented in this manner, and that antiretrovirals may have a persistent protective antiviral effect after drug withdrawal. 20, 21 The ideal drug for chemoprophylaxis should result in high blood levels that are rapidly achieved on dosing, and be maintained for long periods, allowing for oncedaily dosing. It is also preferable to use compounds with a so-called "high genetic barrier" to emergence of drug resistance (eg, drugs to which high-level resistance is not conferred by a single mutation in RT). This would exclude both 3TC and the current NNRTIs. It may be that the protease inhibitors (PIs) are less likely to be effective since their mode of action is post-rather than pre-integrational. However, all active agents against HIV have the potential to be effective in this intervention. The newer receptor blockers and entry inhibitors, especially those which are orally available, such as UK427,857, open up the candidate drug field considerably.
There are well-established, high-risk populations for HIV seroconversion that would be suitable for the evaluation of this intervention strategy. These include seronegative male migrant workers in developing country settings routinely visiting female sex workers, female sex workers, and sexually active uninfected gay men who may be frequently exposed to HIV via infected partners. While barrier methods remain the gold standard for HIV prevention, the use of chemoprophylaxis against HIV infection could benefit those who may be less empowered to insist on condom usage-such as women in commercial sex work, or gay men who choose not to use them. 13 Whether prophylaxis would be used continuously or merely at times of high-risk exposure, and determining the relative benefits of an oral agent versus mucosal protection with a topical virucide currently remain unanswered considerations. However, as with avoidance of malaria, it is possible that a combination approach to HIV prevention would be more successful than a single intervention. Such an intervention must be shown to be cost-effective. Data already exist that post-exposure prophylaxis is cost-effective where reasonable risk of transmission is likely. 22 Additional problems will be the need for long-term safety data in uninfected individuals, and monitoring for the development and effect of resistance to the agents. A recent study of the safety, tolerability, and pharmacokinetics of NVP in high-risk individuals showed that adequate levels to treat, and by inference, prevent HIV infection could be achieved with minimal toxicity. 23 While not reducing our drive to develop an effective vaccine, it is also vital that we do not overlook adjunctive methods of protection against HIV infection. Few believe that vaccines will be completely protective. Moreover, new vaccines may need to be developed on a regular basis, as is done with influenza, to deal with the high mutability of HIV. 24 Studies are urgently required to establish if pre-exposure chemoprophylaxis alone, or in combination with barrier protection is an appropriate response to an epidemic for which an effective vaccine remains elusive, and possibly unattainable. Testing the safety and efficacy of this approach will not be simple and will take time. However, for the populations at greatest risk of HIV infection, including younger gay men and commercial sex workers, the additional benefits of chemoprophylaxis may weigh positively against the risk of drug toxicity. Well-designed studies are needed to determine the benefits and risks of HIV prevention strategies. ■
